Jonathan W Friedberg

Jonathan W Friedberg

UNVERIFIED PROFILE

Are you Jonathan W Friedberg?   Register this Author

Register author
Jonathan W Friedberg

Jonathan W Friedberg

Publications by authors named "Jonathan W Friedberg"

Are you Jonathan W Friedberg?   Register this Author

100Publications

3612Reads

10Profile Views

Patients with diffuse large B-cell lymphoma requiring urgent treatment: its implication on trial design and interpretation.

Leuk Lymphoma 2019 Jul 8:1-4. Epub 2019 Jul 8.

James P. Wilmot Cancer Center, Division of Hematology and Oncology, University of Rochester Medical Center , Rochester , NY , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1639172DOI Listing
July 2019

Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma.

Clin Lymphoma Myeloma Leuk 2018 12 29;18(12):781-787. Epub 2018 Aug 29.

Wilmot Cancer Institute, Strong Memorial Hospital, Rochester, NY.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21522650183039
Publisher Site
http://dx.doi.org/10.1016/j.clml.2018.08.014DOI Listing
December 2018

Burkitt lymphoma- a rare but challenging lymphoma.

Best Pract Res Clin Haematol 2018 09 23;31(3):279-284. Epub 2018 Jul 23.

James P. Wilmot Cancer Institute, University of Rochester Medical Center, 601 Elmwood Avenue Box 704, Rochester, NY, 14642, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2018.07.013DOI Listing
September 2018

Progress in Advanced-Stage Follicular Lymphoma.

J Clin Oncol 2018 08 1;36(23):2363-2365. Epub 2018 Jun 1.

Jonathan W. Friedberg, University of Rochester, Rochester, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.79.3083DOI Listing
August 2018

Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016.

J Clin Oncol 2018 03 22;36(7):697-703. Epub 2018 Jan 22.

Mazyar Shadman, Ajay K. Gopal, David G. Maloney, and Oliver W. Press, University of Washington and Fred Hutchinson Cancer Research Center; Hongli Li and Michael LeBlanc, SWOG Statistical Center, Seattle, WA; Lisa Rimsza, Mayo Clinic Arizona, Scottsdale; Catherine M. Spier, University of Arizona, Tucson, AZ; John P. Leonard, Weill Cornell Medical College, New York; Jonathan W. Friedberg, Wilmot Cancer Institute, University of Rochester, Rochester, NY; Mark S. Kaminski, University of Michigan Health System, Ann Arbor, MI; Rita M. Braziel, Oregon Health & Science University, Portland, OR; Bruce D. Cheson, Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC; Shaker Dakhil, University of Kansas School of Medicine-Wichita, Wichita, KS; Sonali M. Smith, University of Chicago Medicine, Chicago, IL; and Richard I. Fisher, Fox Chase Cancer Center and Temple University School of Medicine, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.74.5083
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.74.5083DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553811PMC
March 2018

Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015.

Hematol Oncol 2017 Dec 4;35(4):397-407. Epub 2017 Apr 4.

Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2411DOI Listing
December 2017

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

N Engl J Med 2017 12 10;377(26):2531-2544. Epub 2017 Dec 10.

From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N., J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A. Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University, Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.), University of California at Los Angeles, Los Angeles (J.M.T.), University of California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B., J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California; Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center, Bronx (I.B.), and the University of Rochester School of Medicine, Rochester (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.), Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H., M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.); University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert, AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (I.A.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1707447DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882485PMC
December 2017

State of the Science: Cancer Complementary and Alternative Medicine Therapeutics Research-NCI Strategic Workshop Highlights of Discussion Report.

J Natl Cancer Inst Monogr 2017 11;2017(52)

Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD; National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD; Memorial Sloan Kettering Cancer Center, New York, NY; University of Kansas, Lawrence, KS; University of Florida, Gainsville, FL; Yale University, New Haven, CT; University of Iowa, Iowa City, IA; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; University of Rochester Medical Center, Rochester, NY; Columbia University Medical Center, New York, NY; The University of Texas MD Anderson Cancer Center, Houston, TX; Peking University Cancer Hospital, Beijing, China; University of Pittsburgh, Pittsburgh, PA; Weill Cornell Medicine at Cornell University, New York, NY; Bastyr University, Kenmore, WA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; Tsinghua University, Beijing, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jncimonographs/lgx003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061228PMC
November 2017

How I treat double-hit lymphoma.

Blood 2017 08 9;130(5):590-596. Epub 2017 Jun 9.

James P. Wilmot Cancer Institute, University of Rochester, Rochester, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-04-737320DOI Listing
August 2017

Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.

J Clin Oncol 2017 Jun 14;35(16):1803-1813. Epub 2017 Mar 14.

James N. Kochenderfer, Robert P.T. Somerville, Tangying Lu, Victoria Shi, Stephanie L. Goff, James C. Yang, Richard M. Sherry, Christopher A. Klebanoff, Udai S. Kammula, Constance M. Yuan, Mark J. Roschewski, Steven A. Feldman, Lori McIntyre, Mary Ann Toomey, and Steven A. Rosenberg, National Cancer Institute, National Institutes of Health, Bethesda, MD; Adrian Bot, John Rossi, Allen Xue, Marika Sherman, and Arianne Perez, Kite Pharma, Santa Monica, CA; Tatyana Feldman, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; and Jonathan W. Friedberg, University of Rochester School of Medicine, Rochester, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.71.3024
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.71.3024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455597PMC
June 2017

Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy.

Blood 2017 06 21;129(22):3037-3039. Epub 2017 Mar 21.

Department of Medicine, James P. Wilmot Cancer Center, University of Rochester, Rochester, NY; and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-12-757740DOI Listing
June 2017

Chemotherapy free treatment of indolent lymphoma.

Hematol Oncol 2017 Jun;35 Suppl 1:20-24

Wilmot Cancer Institute, University of Rochester, Rochester, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2395DOI Listing
June 2017

Reassessment of Anti-CD20 Therapy in Lymphoid Malignancies: Impact, Limitations, and New Directions.

Oncology (Williston Park) 2017 05;31(5):402-11

View Article

Download full-text PDF

Source
May 2017

Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.

J Natl Cancer Inst 2017 04 31;109(4). Epub 2016 Dec 31.

Affiliations of authors: NYU Perlmutter Cancer Center, New York, NY (CSD); BC Cancer Agency Centre for Lymphoid Cancer, Vancouver, BC, Canada (JMC); Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY (JWF); Department of Medicine, Weil Cornell University, New York, NY (JPL); Oncology Division, Department of Medicine, Washington University, St. Louis, MO (BSK, NLB); Division of Cancer Treatment and Diagnosis (RFL) and Coordinating Center for Clinical Trials (LB), Tufts Cancer Center and Division of Hematology/Oncology, Tufts University School of Medicine, Boston, MA (AME); Stanford Cancer Institute, Stanford University Medical School, Stanford, CA (RTH); Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Columbia University Medical Center, New York, NY (KMK); Department of Medicine, University of Arizona Cancer Center, Tucson, AZ (DOP); Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY (AY); Department of Radiology, Mount Sinai Hospital, New York, NY (LK).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw249DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059238PMC
April 2017

Recommendations for Clinical Trial Development in Follicular Lymphoma.

J Natl Cancer Inst 2017 03 31;109(3). Epub 2016 Dec 31.

Affiliations of authors: The Ohio State University, Columbus, OH (KM); University of Rochester Medical Center, Rochester, NY (PMB); Georgetown University Hospital, Washington, DC (BDC); Division of Cancer Treatment and Diagnosis (RFL) and Coordinating Center for Clinical Trials (LB), National Cancer Institute, Bethesda, MD; Department of Medicine, Oncology Division, Washington University, St. Louis, MO (BSK); Department of Medicine, Weil Cornell University, New York, NY (JPL); The University of Texas MD Anderson Cancer Center, Houston, TX (NF); Northwestern University, Chicago, IL (LIG); University of Iowa, Iowa City, IA (BKL); Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester, Rochester, NY (JWF); Mayo Clinic, Rochester, MN (SMA).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw255DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059137PMC
March 2017

Introduction to Genomics in Hematologic Malignancy.

J Clin Oncol 2017 03 13;35(9):927-928. Epub 2017 Feb 13.

Benjamin L. Ebert, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Jonathan W. Friedberg, University of Rochester Wilmot Cancer Institute, Rochester, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.2827DOI Listing
March 2017

Recommendations for Clinical Trial Development in Mantle Cell Lymphoma.

J Natl Cancer Inst 2017 01 31;109(1). Epub 2016 Dec 31.

Affiliations of authors: Division of Hematology and Medical Oncology, Oregon Health and Science (OHSU) University Knight Cancer Institute, Portland, OR (SES); Clinical Research Division, Fred Hutchinson Cancer Research Center/ Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA (BGT, AKG); Department of Medicine, Weill Cornell Medicine, New York, NY (PM, JPL); John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ (AHG); Department of Medicine III, Klinikum der Universität München, Campus Grosshadern, Munich, Germany (MPD); Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA (ML); Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester, Rochester, NY (JWF); Coordinating Center for Clinical Trials, National Cancer Institute, National Institutes of Health, Bethesda, MD (LB); HIV and AIDS Malignancy Branch, Center for Cancer Research, and Clinical Investigations Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD (RFL); Department of Medicine, Oncology Division, Washington University, St. Louis, MO (BSK); Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH (MRS).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw263DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059122PMC
January 2017

Reply to H.J.A. Adams et al and E.A. Hawkes et al.

J Clin Oncol 2017 01 28;35(3):373. Epub 2016 Oct 28.

Oliver W. Press, Fred Hutchinson Cancer Research Center, Seattle, WA, and Jonathan W. Friedberg, James P. Wilmot Cancer Institute, University of Rochester, Rochester, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.7979DOI Listing
January 2017

General Biomarker Recommendations for Lymphoma.

J Natl Cancer Inst 2016 12 16;108(12). Epub 2016 Dec 16.

Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ (LR), Department of Pathology and Laboratory Medicine, University of North Carolina Medical School, Chapel Hill, NC (YF), Center for Cancer Research, National Cancer Institute, Bethesda, MD (LMS), Department of Medicine, Weill Cornell Medical College, New York, NY (AM), Department of Pathology and Laboratory Medicine, British Columbia Cancer Agency, Vancouver, BC, Canada (RG), Clinical Cancer Research Unit, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada (MC), Coordinating Center for Clinical Trials, National Cancer Institute, Bethesda, MD (LB), Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE (KF), Department of Pathology and Laboratory Medicine, Cleveland Clinic Foundation, Cleveland, OH (ED), Department of Pathology, City of Hope Medical Center, Duarte, CA (JWCC), Biometrics Research Branch, National Cancer Institute, Bethesda, MD (LM), Department of Medicine, Weill Cornell Medicine, New York, NY (JPL), Department of Medicine, Oncology Division, Washington University, St. Louis, MO (BSK), Clinical Investigations Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD (RFL), Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester, Rochester, NY (JWF), Department of Radiology, Mount Sinai Medical Center New York, NY (LK).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw250DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6080362PMC
December 2016

Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.

J Natl Cancer Inst 2016 12 16;108(12). Epub 2016 Dec 16.

Department of Medicine, Mayo Clinic, Rochester, MN (GSN); Department of Internal Medicine, Ohio State University, Columbus, OH (KAB); Department of Medicine, Oncology Division, Washington University, St. Louis, MO (BSK); Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester, Rochester, NY (JWF); Coordinating Center for Clinical Trials (LB), Division of Cancer Treatment and Diagnosis (RFL), and Center for Cancer Research (WHW), National Cancer Institute, National Institute of Health, Bethesda, MD; Division of Oncology, University of Washington, Seattle WA (DGM); British Colombia Cancer Agency, Vancouver, BC (LHS); Department of Medicine, University of Virginia, Charlottesville, VA (MEW); Department of Medicine, Weil Cornell University, New York, NY (JPL); Department of Medicine, University of Chicago, Chicago, IL (SMS).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw257DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6080361PMC
December 2016

Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective.

Cancer Med 2016 11 3;5(11):3059-3067. Epub 2016 Oct 3.

James P Wilmot Cancer Institute and Department of Medicine, University of Rochester Medical Center, Rochester, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.879DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5119960PMC
November 2016

Using the pathology report in initial treatment decisions for diffuse large B-cell lymphoma: time for a precision medicine approach.

Hematology Am Soc Hematol Educ Program 2015 ;2015:618-24

Samuel Durand Professor of Medicine, University of Rochester, Rochester, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2015.1.618DOI Listing
October 2016

Patterns and Timing of Failure for Diffuse Large B-Cell Lymphoma After Initial Therapy in a Cohort Who Underwent Autologous Bone Marrow Transplantation for Relapse.

Int J Radiat Oncol Biol Phys 2016 10 27;96(2):372-378. Epub 2016 May 27.

Department of Radiation Oncology, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2016.05.021DOI Listing
October 2016

High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex.

J Natl Compr Canc Netw 2016 10;14(10):1274-1281

From Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Biostatistics and Data Coordinating Center, City of Hope National Medical Center, Duarte, California; Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas; Hematology and Stem Cell Transplantation, City of Hope National Medical Center, Duarte, California; University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan; Departments of Medicine and Immunology, Roswell Park Cancer Institute, Buffalo, New York; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Medicine/Lymphoma, Memorial Sloan Kettering Cancer Center, New York, New York; and James P. Wilmot Cancer Center, University of Rochester, Rochester, New York.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531178PMC
http://dx.doi.org/10.6004/jnccn.2016.0136DOI Listing
October 2016

Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736.

J Clin Oncol 2016 09 5;34(25):2997-3004. Epub 2016 Jul 5.

Deborah M. Stephens, University of Utah, Salt Lake City, UT; Hongli Li and Michael L. LeBlanc, Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Soham D. Puvvada and Daniel Persky, University of Arizona, Tucson, AZ; Jonathan W. Friedberg, Wilmot Cancer Institute, University of Rochester, Rochester, NY; and Sonali M. Smith, University of Chicago, Chicago, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.4582DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012710PMC
September 2016

US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.

J Clin Oncol 2016 06 11;34(17):2020-7. Epub 2016 Apr 11.

Oliver W. Press, Fred Hutchinson Cancer Research Center, and the University of Washington; Hongli Li and Michael LeBlanc, Fred Hutchinson Cancer Research Center, Seattle, WA; Heiko Schöder, David J. Straus, Craig H. Moskowitz, and Ariela Noy, Memorial Sloan Kettering Cancer Center; John P. Leonard, Weill Cornell Medical College and New York Presbyterian Hospital, New York City; Paul M. Barr and Jonathan W. Friedberg, University of Rochester Medical Center, Rochester, NY; Lisa M. Rimsza, University of Arizona, Tucson, AZ; Nancy L. Bartlett and Brad S. Kahl, Washington University School of Medicine, St. Louis, MO; Andrew M. Evens, Tufts Medical Center; Ann S. LaCasce, Dana-Farber Cancer Institute, Boston, MA; Erik S. Mittra, Stanford University Medical Center, Stanford, CA; John W. Sweetenham, Huntsman Cancer Hospital, Salt Lake City, UT; Michelle A. Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Michael V. Knopp, The Ohio State University, Columbus; Eric D. Hsi, Cleveland Clinic Foundation; James R. Cook, Cleveland Clinic, Cleveland, OH; Mary Jo Lechowicz, Winship Cancer Institute of Emory University, Atlanta, GA; Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, BC; Bruce D. Cheson, Georgetown University Hospital, Washington DC; and Richard I. Fisher, Fox Chase Cancer Center, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.1119DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966513PMC
June 2016

Consolidative Radioimmunotherapy After Chemoimmunotherapy in Patients With Histologic Transformation of Indolent Non-Hodgkin Lymphoma.

Clin Lymphoma Myeloma Leuk 2016 Jun 2;16(6):322-328.e2. Epub 2016 Apr 2.

Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2016.03.014DOI Listing
June 2016

Advancing radioimmunotherapy and its future role in non-Hodgkin lymphoma.

Future Oncol 2015 ;11(10):1543-53

Wilmot Cancer Institute, University of Rochester Medical Center, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.15.1DOI Listing
February 2016

Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells.

Br J Haematol 2015 Oct 18;171(2):205-209. Epub 2015 Jun 18.

Department of Medicine and James P. Wilmot Cancer Institute, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13562DOI Listing
October 2015

Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.

J Clin Oncol 2015 Oct 17;33(30):3467-74. Epub 2015 Aug 17.

Laurie H. Sehn, Centre for Lymphoid Cancer, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia; Tara Baetz, Queen's University, Kingston General Hospital, Kingston; Rena Buckstein, Sunnybrook Health Sciences Center; Michael Crump, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Andre Goy and Luis E. Fayad, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; Fritz C. Offner, Institute of Hematology and Medical Oncology, University of Bologna; Pier Luigi Zinzani, Institute of Hematology "Seràgnoli" University of Bologna, Bologna; Giovanni Martinelli, European Institute of Oncology, Milano; Gianluca Gaidano, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; M. Dolores Caballero, University Hospital of Salamanca, Salamanca, Spain; Ole Gadeberg, Vejle Hospital, Vejle, Denmark; Andrew D. Zelenetz, Memorial Sloan Kettering Cancer Center, New York; Jonathan Friedberg, James P. Wilmot Cancer Center, University of Rochester, Rochester, NY; Branimir Jadkisic, Clinical Hospital Merkur, University of Zagreb, Zagreb, Croatia; Swaminathan Padmanabhan Iyer, Houston Methodist Cancer Center, Weill Cornell Medical College, Houston, TX; Deniz Sahin and Günter Fingerle-Rowson, Roche, Basel, Switzerland; Akiko Chai, Genentech BioOncology, South San Francisco, CA; Oliver Press, Fred Hutchinson Cancer Research Center, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.2139DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087315PMC
October 2015

Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.

J Clin Oncol 2015 Aug 29;33(23):2516-22. Epub 2015 Jun 29.

Carla Casulo and Jonathan W. Friedberg, University of Rochester, Rochester; Jonathan W. Friedberg, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Byrtek and Keith L. Dawson, Genentech, South San Francisco, CA; Xiaolei Zhou, RTI Health Solutions, Research Triangle Park, NC; Charles M. Farber, Carol G. Simon Cancer Center, Morristown, NJ; Christopher R. Flowers, Emory University, Atlanta, GA; John D. Hainsworth, Sarah Cannon Research Institute, Nashville, TN; Matthew J. Maurer and James R. Cerhan, Mayo Clinic, Rochester, MN; and Brian K. Link, University of Iowa, Iowa City, IA.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/06/24/JCO.2014.59
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.59.7534
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.59.7534DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879714PMC
August 2015

Follicular lymphoma: first-line treatment without chemotherapy for follicular lymphoma.

Curr Treat Options Oncol 2015 Jul;16(7):32

University of Rochester Medical Center, 601 Elmwood Ave, Box 704, Rochester, NY, 14642, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-015-0351-7DOI Listing
July 2015

Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.

J Clin Oncol 2015 Jul 15;33(21):2399-404. Epub 2015 Jun 15.

Paul M. Barr and Jonathan W. Friedberg, University of Rochester, Rochester; Steven M. Horwitz, Memorial Sloan Kettering Cancer Center, New York, NY; Hongli Li and Michael LeBlanc, SWOG Statistical Office, Seattle, WA; Catherine Spier, University of Arizona College of Medicine, Tucson, AZ; Daruka Mahadevan, Mansoor Ul Haq, and Bryan D. Huber, University of Tennessee Health Sciences Center, Memphis, TN; Christopher R. Flowers, Emory University, Atlanta, GA; Nina D. Wagner-Johnston and Nancy L. Bartlett, Washington University School of Medicine, St. Louis, MO; Richard I. Fisher, Temple University, Philadelphia, PA; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; Sonali M. Smith, The University of Chicago, Chicago, IL; and Brad S. Kahl, University of Wisconsin, Madison, WI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.6327DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500834PMC
July 2015

Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial.

J Clin Oncol 2015 Jun 20;33(17):1936-42. Epub 2015 Apr 20.

Ranjana H. Advani, Richard T. Hoppe, and Sandra J. Horning, Stanford University, Stanford; Joseph M. Tuscano, University of California, Davis Cancer Center, Sacramento, CA; Fangxin Hong, Dana-Farber Cancer Institute, Boston, MA; Richard I. Fisher and Jonathan W. Friedberg, University of Rochester, Rochester, NY; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; K. Sue Robinson, Queen Elizabeth II Health Science Center, Halifax, Nova Scotia; Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, British Columbia; Douglas A. Stewart, Tim Baker Cancer Institute, Calgary, Alberta, Canada; Henry Wagner Jr, Penn State Cancer Institute, Hershey, PA; Patrick J. Stiff, Loyola University Medical Center, Maywood; Leo I. Gordon, Northwestern University, Chicago, IL; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; Brad S. Kahl, University of Wisconsin, Madison, WI; Kristie A. Blum, Ohio State University, Columbus, OH; and Thomas M. Habermann, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/04/15/JCO.2014.57
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.57.8138
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.57.8138DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451176PMC
June 2015

Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies.

J Clin Oncol 2015 May 30;33(13):1482-90. Epub 2015 Mar 30.

Jennifer L. Kelly and Jonathan W. Friedberg, James P. Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, NY; Gilles Salles, Hospices Civils de Lyon, Université Claude Bernard Lyon-1, Pierre Benite; Pauline Brice, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Paris; Olivier Casasnovas, Centre Hospitalo-Universitaire de Dijon, Dijon; Pierre Soubeyran, Institut Bergonié and Université Victor Segalen Bordeaux 2, Bordeaux; Corinne Haioun, Assistance Publique-Hôpitaux de Paris, Hôpital Henri Mondor, Créteil; Luc Xerri, Institut Paoli Calmettes, Marseille; Hervé Tilly, Centre Henri Becquerel, Rouen, France; Bryan Goldman, Oliver Press, and Michael LeBlanc, SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Richard I. Fisher, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, PA; and Lisa Rimsza, University of Arizona, Tucson, AZ.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/03/30/JCO.2014.57
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.57.5092
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.57.5092DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404425PMC
May 2015

Double hit diffuse large B-cell lymphomas: diagnostic and therapeutic challenges.

Chin Clin Oncol 2015 Mar;4(1)

Samuel Durand Professor of Medicine, University of Rochester, Rochester, NY 14642, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2304-3865.2015.03.02DOI Listing
March 2015

Impact of dietary supplements, obesity and treatment initiation on serum vitamin D levels in patients with lymphoma.

Leuk Lymphoma 2015 Feb 15;56(2):508-11. Epub 2014 Jul 15.

Division of Endocrinology, Department of Medicine.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2014.919633DOI Listing
February 2015

Transformed follicular non-Hodgkin lymphoma.

Blood 2015 Jan 11;125(1):40-7. Epub 2014 Dec 11.

Division of Hematology and Oncology and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-04-516815DOI Listing
January 2015

End of rituximab maintenance for low-tumor burden follicular lymphoma.

J Clin Oncol 2014 Oct 25;32(28):3093-5. Epub 2014 Aug 25.

James P. Wilmot Cancer Institute, University of Rochester, Rochester, NY

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.8328DOI Listing
October 2014

Medical history, lifestyle, family history, and occupational risk factors for sporadic Burkitt lymphoma/leukemia: the Interlymph Non-Hodgkin Lymphoma Subtypes Project.

J Natl Cancer Inst Monogr 2014 Aug;2014(48):106-14

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health Bethesda, MD (SMM, LMM, JNS); Center for Epidemiology and Computational Biology, Health Sciences Practice, Exponent, Inc, Menlo Park, CA, Division of Epidemiology, Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA (ETC); Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Institut Catala d'Oncologia, IDIBELL, Barcelona, Spain, CIBER Epidemiologia y Salud Publica, Barcelona, Spain (LC, SdS); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK (TL); School of Medicine and Dentistry, University of Rochester, Rochester, NY (JK, JWF); Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA (WC); Descriptive Epidemiology, Genetics and Cancer Prevention Group, Girona Biomedical Research Institute, Catalan Institute of Oncology-Girona, Girona, Spain (RM-G); Department of Health Sciences Research, Mayo Clinic, Rochester, MN (SLS); Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (BMB); Department of Pathology, City of Hope National Medical Center, Duarte, CA (DDW).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jncimonographs/lgu003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155458PMC
August 2014

Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.

J Natl Cancer Inst Monogr 2014 Aug;2014(48):130-44

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD (LMM, SMM, JSC, PH, NR, AB, KPC, QL, SIB, MSL, JNS); Department of Health Sciences Research (SLS, JRC, TMH), Division of Hematology (TGC), and Divison of General Internal Medicine (ML), College of Medicine, Mayo Clinic, Rochester, MN; Department of Cancer Etiology, City of Hope Beckman Research Institute, Duarte, CA (SSW, LB, AL); Prince of Wales Clinical School, University of New South Wales, Sydney, Australia (CMV); Department of Epidemiology, Comprehensive Cancer Center, University of Alabama, Birmingham, AL (CFS); Department of Epidemiology and Biostatistics, School of Medicine, University of California San Francisco, San Francisco, CA (PMB, EAH); Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Institut Català d' Oncologia, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain, CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain (SdS, YB); Unit of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden (KES); Department of Health Studies, University of Chicago, Chicago, IL (BCHC); Department of Environmental Health Sciences (YZ, TZ) and Department of Biostatistics (TRH), Yale School of Public Health, New Haven, CT; INSERM, Centre for Research in Epidemiology and Population Health (CESP), U1018, Environmental Epidemiology of Cancer Group, Villejuif, France, Univ Paris Sud, UMRS 1018, Villejuif, France (AM, JC, LO); Registry of Hematological Malignancies in Gironde, Bergonié Institute, 33076 Bordeaux, France (AM); Department of Histopathology, Douglass Hanly Moir Pathology, Macquarie Park, Australia, The Australian School of Advanced Medicine, Macquarie University, Sydney, Australia (JJT); Department of Medical Epidemiology and Biostatistics (H-OA) and Department of Oncology and Pathology (BG), Karolinska Institutet, Stockholm, Swed

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jncimonographs/lgu013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155467PMC
August 2014